pharmaceutical investing Alexion Announces Successful Phase 3 PREVENT Study of Soliris (Eculizumab) in Patients with Neuromyelitis Optica Spectrum Disorder
pharmaceutical investing Alexion Submits Application for Approval of ALXN1210 as a Treatment for Patients with Paroxysmal Nocturnal Hemoglobinuria in the EU
Syntholene Energy Signs Site Lease and Receives Construction Permit at Historic Husavik Power Station for Demonstration Facility
Metalsource Mining Intersects 48.04 g/t AuEq over 12.62m, Including 210.72 g/t AuEq over 2.74m, Extends Mineralization down Dip 195m, Continues to Expand Gold, Silver and Base Metal Mineralization
